Treating or preventing restless legs syndrome using prodrugs of GABA analogs
First Claim
Patent Images
1. A method of treating or preventing restless legs syndrome in a patient comprising administering to the patient in need of such treatment or prevention a therapeutically effective amount of a prodrug of a GABA analog, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
6 Assignments
0 Petitions
Accused Products
Abstract
Disclosed herein are methods of using prodrugs of gamma aminobutyric acid (GABA) analogs and pharmaceutical compositions thereof to treat or prevent restless legs syndrome in humans, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating or preventing restless legs syndrome.
-
Citations
28 Claims
- 1. A method of treating or preventing restless legs syndrome in a patient comprising administering to the patient in need of such treatment or prevention a therapeutically effective amount of a prodrug of a GABA analog, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
-
2. A method of improving sleep in a patient with restless legs syndrome comprising administering to the patient a therapeutically effective amount of a prodrug of a GABA analog, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
- 23. A method of treating or preventing restless legs syndrome in a patient comprising administering to the patient in need of such treatment or prevention a pharmaceutical composition comprising a therapeutically effective amount of a prodrug of a GABA analog, or a pharmaceutically acceptable salt, hydrate or solvate thereof and a pharmaceutically acceptable vehicle.
- 25. A pharmaceutical composition for treating a patient suffering from restless legs syndrome comprising a therapeutically effective amount of a prodrug of a GABA analog or a pharmaceutically acceptable salt, hydrate or solvate thereof and a pharmaceutically acceptable vehicle.
- 27. A pharmaceutical composition suitable for preventing restless legs syndrome in a patient at risk of restless legs syndrome comprising a therapeutically effective amount of a prodrug of a GABA analog or a pharmaceutically acceptable salt, hydrate or solvate thereof and a pharmaceutically acceptable vehicle.
Specification